SecBot SecBot

IQV

IQVIA HOLDINGS INC.
NYSE· Services-Commercial Physical & Biological Research· Inc. DE· CIK 0001478242 Biotech & Drug Discovery
$264.73 −0.39 (−0.15%)
Nov 16 4:00 PM ET · prev $265.12
Market cap
$44.7B
Large cap
Consensus
Buy
92% Buy or better · 26 analysts
Median target
$310.00
+17% · range $268.00–346.00
1 year
+22.5%
from $216.12 · Nov 17
30 days
−0.4%
from $265.88
52-week range
$156.66–279.36
−5% from high · low Apr 29
Avg volume 20D
1.49M
shares / day
Short interest
3.04M
≈1.9% of shares · +1.7%
Days to cover
2.1
at average volume
Insider net
−$31.1M
0 buyers · 6 sellers · since Feb 9
New fund stakes
9
Q3 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $31.1M.

  • InstitutionsBULLISH

    Q3 2026: 73 added (9 new), 28 trimmed or exited. Largest new: Wcm Investment Management $717.7M, Sound Shore Management /Ct/ $91.1M.

  • AnalystsBULLISH

    24 of 26 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +1.7% to 3.04M shares. 2.1 days to cover, ≈1.9% of shares.

  • TrendRANGE

    1% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 21.

Who's buying

13F· Q3 2026
9
new positions
0
exits
$833.3M
in new stakes · top 3 shown
FundMoveSharesValue
JPMORGAN CHASE & COTRIM4,316,639$1.2B
Artisan Partners Limited PartnershipTRIM3,461,373$930.6M
WCM INVESTMENT MANAGEMENT, LLCNEW2,668,127$717.7M
FMR LLCADD2,104,818$565.9M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD1,903,283$511.7M
FRANKLIN TEMPLETON INCTRIM1,529,650$403.5M
JANE STREET GROUP, LLCDOUBLED1,012,789$272.3M
DEUTSCHE BANK AG\ADD955,153$256.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

26 analysts
Buy 92% rate it Buy or better
Strong Buy9Buy15Hold2Sell0Strong Sell0
12-month targets · 18 analysts

Price is below the lowest target. Median implies +17%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 29, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Oct 28, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Oct 28, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Oct 28, 2026Evercore ISI Group
MAINTAIN
MAINTAINOutperform
Oct 28, 2026Baird
MAINTAIN
MAINTAINOutperform
Oct 14, 2026Stifel
MAINTAIN
MAINTAINBuy
Congressional trades
IQV trades disclosed by members of Congress, with disclosure delay.
3 members · 2 buys / 2 sells
DateMemberType AmountDisclosed
May 27, 2026 Ro KhannaDHouse Spouse account · Iqvia Holdings Inc SELL $1K–$15K Jun 9, 2026 +13d
May 15, 2026 Ro KhannaDHouse Spouse account · Iqvia Holdings Inc BUY $1K–$15K Jun 9, 2026 +25d
Mar 16, 2026 Kevin HernRHouse Joint account · Iqvia Holdings Inc SELL $50K–$100K Apr 3, 2026 +18d
Dec 29, 2025 Markwayne MullinRSenate Joint account · Iqvia Holdings Inc BUY $15K–$50K Jan 16, 2026 +18d

Insider ledger

Form 4
$0
bought · 0 insiders
$31.1M
sold · 6 insiders
DateInsiderTypeValue
Nov 9, 2026
Sherbet Eric
See Remarks
Nov 9, 2026
EXERCISE$1.1M
Nov 9, 2026
Sherbet Eric
See Remarks
Nov 9, 2026
SELL$1.2M
Nov 9, 2026
Sherbet Eric
See Remarks
Nov 9, 2026
TO ISSUER$1.1M
Nov 5, 2026
DANHAKL JOHN G
Director
Nov 5, 2026
AWARD$35.5K
Nov 5, 2026
Fasano Jim
Director
Nov 5, 2026
AWARD$40.8K
Nov 5, 2026
GOGGINS COLLEEN A
Director
Nov 5, 2026
AWARD$38.1K
Nov 5, 2026
Wims Morris Leslie
Director
Nov 5, 2026
AWARD$33.1K
Sep 2, 2026
Berkshire James G.
See Remarks
Sep 2, 2026
SELL$697.2K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
3,041,916
shares short
+1.7%
vs prior settlement
2.1
days to cover
≈1.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 9, 2026 SEC
Eric Sherbet, an officer of IQVIA Holdings Inc., filed a Form 144 notice of intent to sell 4,446 shares of common…
144 · Impact 2/10
Nov 9, 2026 Insider
Sherbet Eric acquired via exercise 8,436 shares
See Remarks @ $131.82 ($1.1M)
Nov 9, 2026 Insider
Sherbet Eric sold 4,446 shares
See Remarks @ $278.83 ($1.2M)
Nov 9, 2026 Insider
Sherbet Eric disposed of 3,990 shares
See Remarks @ $278.74 ($1.1M)
Oct 27, 2026 SEC
IQVIA reported Q3 2026 revenue of $4,428M (up 8.0% YoY) and adjusted diluted EPS of $3.34 (up 11.3% YoY), exceeding…
8-K · Impact 6/10
Oct 27, 2026 Earnings result
IQV Q3 2026 Earnings: EPS $3.34 (+1.0% vs est)
Oct 23, 2026 SEC
A mixed institutional cluster in IQV shows 5 buyers adding $94.4M in new positions (led by Artemis doubling its stake…
INST-CLUSTER · Impact 3/10
Sep 30, 2026 Inst.
JPMORGAN CHASE & CO · TRIM
4,316,639 shares ($1.2B)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 27, 2026
Earnings result
IQV Q3 2026 Earnings: EPS $3.34 (+1.0% vs est)
Oct 13, 2026
Press release
IQVIA entscheidet sich für Veeva-Anwendungen für klinische Abläufe
RESEARCH TRIANGLE PARK, North Carolina, und PLEASANTON, Kalifornien, 13. Oktober 2026 /PRNewswire/ -- IQVIA (NYSE: IQV) und Veeva Systems (NYSE…
Oct 13, 2026
Press release
IQVIA Selects Veeva Clinical Operations Applications
RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced…
Oct 8, 2026
Clinical Trial
Olorofim Aspergillus Infection Study
Phase 3 · COMPLETED
Sep 27, 2026
Trial readout
T-90d Trial Readout: Oregovomab (Phase 3)
Trial: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Sponsor…

Washington

Corporate Lobbying

9 lobbying filings and 2 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

SecBot reports

13 filings · 3 bullish · 0 bearish · 10 neutral
All IQV filing & press-release reports (13)